BillionToOne Selected as Liquid Biopsy Platform for Japan's LC-SCRUM-TRY Study
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 06 2026
0mins
Source: PRnewswire
- Liquid Biopsy Selection: BillionToOne's Northstar Select has been chosen as the liquid biopsy platform for the LC-SCRUM-TRY study, aimed at analyzing genomic characteristics of approximately 2,000 patients with treatment-resistant non-small cell lung cancer through non-invasive methods, thereby enhancing precision in treatment selection.
- Technical Advantage: The Northstar Select single-molecule NGS platform can detect variant allele frequencies as low as 0.15%, significantly outperforming other commercial liquid biopsy tests, ensuring higher sensitivity in clinical applications to meet patient demands for personalized treatment.
- Clinical Validation: The platform's performance in comparative studies with traditional tissue biopsies has led to meeting Medicare coverage criteria, indicating that more advanced cancer patients will benefit from this innovative technology, promoting the accessibility of precision medicine.
- Strategic Collaboration: The partnership with the National Cancer Center Hospital in Japan marks a significant advancement in treatment options for patients with drug-resistant lung cancer, expected to provide more effective therapies and further solidify the company's leadership in the molecular diagnostics field.
Analyst Views on BLLN
About BLLN
BillionToOne, Inc. is a precision diagnostics company that quantifies biology to create molecular diagnostics. The Company's proprietary molecular counting platform is designed to detect and measure deoxyribonucleic acid (DNA) molecules at a single-count level to help improve disease detection. It applies the proprietary technology to non-invasive prenatal screening (Prenatal) and liquid biopsy (Oncology). Its Quantitative Counting Templates (QCTs), power its ability to detect and measure tiny and sparse disease-related DNA fragments, or molecules, at the single base-pair level. These include pregnancy-related DNA that code for recessively inherited conditions such as sickle cell disease and cystic fibrosis and ctDNA in the case of cancer. Its prenatal products include UNITY Complete, UNITY Fetal Risk Screen, UNITY Aneuploidy Screen, UNITY Fetal RhD NIPT, UNITY Fetal Antigen NIPT, and UNITY Fetal Antigen CTA NIPT. Its oncology products include Northstar and Northstar Select.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
